Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IKT-001 · 2 trials · 2 indications
The number of participants who experience a TEAE, serious TEAE or TEAE of special interest will be reported.
Change in Pulmonary Vascular Resistance (PVR)
Change in 6-minute walk distance (6MWD)
| Arm | Type | Description |
|---|---|---|
| IKT-001 | EXPERIMENTAL | IKT-001 tablets for PO administration |
| Placebo | PLACEBO_COMPARATOR | Matching placebo to IKT-001 tablets for PO administration |
| Name | Type | Description |
|---|---|---|
| IKT-001 | DRUG | IKT-001 tablets for PO administration |
| Placebo | DRUG | Placebo to IKT-001 tablets for PO administration |
Inclusion Criteria: * Capable of giving signed informed consent. * Participants who have completed Study IKT-001-201 or any other Phase 2 or 3 controlled clinical study with IKT-001. Exclusion Criteria: * Any of the following clinical laboratory values at screening: * ALT or AST levels \>3× th...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| United Therapeutics Corporation | UTHR | 5 | PHASE3 | Ralinepag |
| Merck & Co., Inc. | MRK | 6 | PHASE3 | Riociguat |
| Insmed Incorporated | INSM | 4 | PHASE3 | Treprostinil Palmitil |
| Johnson & Johnson | JNJ | 4 | PHASE3 | Selexipag |
| Liquidia Corporation | LQDA | 4 | PHASE3 | L606 |
| Tenax Therapeutics, Inc. | TENX | 3 | PHASE3 | TNX-103 |
| Inhibikase Therapeutics, Inc. | IKT | 1 | PHASE3 | IKT-001 |
| Gossamer Bio, Inc. | GOSS | 2 | PHASE3 | Seralutinib |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE2 | REGN13335 |
| Pfizer Inc. | PFE | 1 | PHASE2 | PF-07868489 |
| Tectonic Therapeutic Inc | TECX | 1 | PHASE2 | TX000045- Dose A, TX000045- Dose B |
| Abbott Laboratories | ABT | 1 | N/A | Undisclosed |
IKT-001 is an investigational small molecule being developed for the treatment of Pulmonary Arterial Hypertension (PAH), a form of high blood pressure in the arteries of the lungs. It is currently in Phase 3 clinical development and has not yet been approved by regulatory authorities.
IKT-001 targets BCR-ABL, a fusion protein kinase. By inhibiting this target, the drug is being studied for its potential effects in Pulmonary Arterial Hypertension (PAH). The drug is currently in Phase 3 clinical trials to evaluate its safety and efficacy in patients with this condition.
IKT-001 is being developed by Inhibikase Therapeutics, Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol IKT. The company is conducting Phase 3 clinical trials to evaluate the drug for the treatment of Pulmonary Arterial Hypertension (PAH).
IKT-001 is currently in Phase 3 clinical development for Pulmonary Arterial Hypertension (PAH). It is an investigational drug and has not been approved by the FDA. The drug has received Orphan Drug designation, which is granted to therapies intended for rare diseases.
IKT-001 is being studied in two Phase 3 clinical trials. The first trial, NCT07365332, is an adaptive study in Pulmonary Arterial Hypertension (PAH) that is currently recruiting participants across multiple countries. The second trial, NCT07632898, is an open-label study in PAH that has not yet started recruiting.
IKT-001 is a distinct investigational drug developed by Inhibikase Therapeutics. While it targets BCR-ABL, a kinase also targeted by imatinib, IKT-001 is being studied specifically for Pulmonary Arterial Hypertension (PAH) and is not the same compound as imatinib. It is currently in Phase 3 clinical trials.